Recent integrated genomic studies have indicated a greater tendency for the occurrence of HER2 amplification and recurrent mutations in cervical adenocarcinoma than in squamous cell carcinoma [27, 28]. The gene discussed is ERBB2; the disease is cervical adenocarcinoma.